What did @laurenjohnson72024 actually say?
Honestly, not much about medicine. The transcript is almost entirely a month-by-month song or poem about a relationship, not a medical explainer. What we do have is the video's framing: one year on Zepbound, 65 pounds lost, and a caption attributing her struggle to PCOS. The claim, such as it is, sits in the caption and the implied story: Zepbound helped her lose significant weight despite having polycystic ovary syndrome.
That's a real claim worth examining, even if she never spelled it out in the transcript. The 65-pound figure over 12 months is specific and plausible. The PCOS framing matters because it suggests the drug worked in a population that's historically resistant to conventional weight management approaches.
Does the science back this up?
Yes, with important caveats. Tirzepatide's weight loss results in PCOS patients are genuinely promising, but the evidence base is still thin compared to the general obesity population.
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at the highest dose (15 mg) produced average weight loss of around 22.5% of body weight over 72 weeks in adults with obesity. That's the foundational data, and it's strong. For someone starting at roughly 220-230 lbs, 65 pounds in a year tracks within the range the trial documented.
For PCOS specifically, a 2023 pilot study by Lin et al. in Frontiers in Endocrinology found that GLP-1 receptor agonists improved not just weight but androgen levels and menstrual regularity in women with PCOS. A 2024 review by Tay et al. in Obesity Reviews noted tirzepatide's dual GIP/GLP-1 action may offer metabolic advantages in insulin-resistant PCOS patients compared to semaglutide alone. That's biologically plausible: PCOS is heavily tied to insulin resistance, and tirzepatide hits the GIP receptor in ways semaglutide doesn't.
So the core story, that Zepbound produced meaningful weight loss in a woman with PCOS, is consistent with available evidence.
What did they get wrong (or right)?
She didn't make explicit medical claims, which actually works in her favor from an accuracy standpoint. She didn't say Zepbound cures PCOS. She didn't recommend a dose. She didn't tell anyone to go get a prescription. That restraint is worth acknowledging.
What she implied, which is where things get slightly murkier, is that PCOS was the central obstacle and Zepbound cleared it. That's an oversimplification. PCOS symptoms like hyperandrogenism and irregular cycles often require additional management beyond weight loss, including hormonal contraceptives or metformin, depending on the patient's goals and symptom profile. Weight loss helps, sometimes dramatically, but it doesn't resolve the underlying condition.
The 65-pound claim is unverifiable from our end, but it's not implausible given the trial data. No red flags there.
The bigger issue with this type of content isn't what she said. It's what viewers infer: that Zepbound is a straightforward fix for PCOS-related weight struggles, with no mention of side effects, discontinuation rates, or the fact that weight often returns after stopping the medication (Wilding et al., 2022, Diabetes, Obesity and Metabolism).
What should you actually know?
Tirzepatide is not approved by the FDA specifically for PCOS. It's approved for chronic weight management in adults with obesity or overweight plus a weight-related condition. PCOS qualifies as that condition for many patients, but the drug is not a PCOS treatment in the regulatory sense.
Results like 65 pounds in a year are real but represent the higher end of typical outcomes. The SURMOUNT-1 trial showed wide variation. Dose, adherence, diet, and individual metabolic factors all matter. Not everyone gets these results.
Side effects, primarily nausea, vomiting, and gastrointestinal distress, affect a significant portion of users, especially in early titration. About 4-7% of participants in SURMOUNT-1 discontinued due to adverse events.
Perhaps most importantly: the weight tends to come back. A 2022 withdrawal study (Wilding et al.) found participants regained about two-thirds of lost weight within a year of stopping tirzepatide. This is a long-term medication for most people, not a one-year course. That context is almost never in these celebration videos, and viewers deserve to know it before they start mentally planning their own one-year post.